Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome during treatment with the bivalent CD20xCD3 bispecific antibody glofitamab

Key Points

• The study aims to investigate the occurrence of hemophagocytic lymphohistiocytosis-like syndrome during treatment with glofitamab.
• Conducted an observational analysis of patients receiving glofitamab
• Monitored immune effector cell responses
• Evaluated clinical outcomes related to hemophagocytic lymphohistiocytosis
• Identified cases of hemophagocytic lymphohistiocytosis-like syndrome during treatment
• Noted variations in immune response among patients
• Suggested a correlation between glofitamab treatment and immune system dysregulation